Valuation: PTC Therapeutics, Inc.

Market Cap 7B 6.14B 5.66B 5.3B 9.94B 661B 10.14B 68.03B 26.32B 327B 26.3B 25.72B 1,132B P/E 2026 *
95.3x
P/E 2027 * 33.8x
Enterprise Value 5.22B 4.58B 4.22B 3.95B 7.41B 492B 7.56B 50.7B 19.62B 243B 19.6B 19.17B 844B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 3.93x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week+6.90%
Current month+14.33%
1 month+19.49%
3 months+27.67%
6 months+7.47%
Current year+11.15%
1 week 79.5
Extreme 79.505
87.03
1 month 67.51
Extreme 67.51
87.03
Current year 61.43
Extreme 61.43
87.03
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
06-22Fiscal year

Chief Technology Officer

71,247 0.0859%
06-17Fiscal year

General Counsel

31,506 0.0380%
06-17Fiscal year

Controller/Auditor

59,058 0.0712%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+6.90%+69.40%+105.28% 7B
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.38%+7.89%+34.83%+59.62% 362.31B
Weighted average by Cap. +3.84%+8.92%+41.81%+80.22%

Financials

2026 *2027 *
Net sales 1.17B 1.03B 948M 888M 1.66B 111B 1.7B 11.4B 4.41B 54.7B 4.41B 4.31B 190B 1.31B 1.15B 1.06B 993M 1.86B 124B 1.9B 12.75B 4.93B 61.19B 4.93B 4.82B 212B
Net income 65.46M 57.39M 52.9M 49.53M 92.87M 6.17B 94.8M 636M 246M 3.05B 246M 240M 10.58B 178M 156M 144M 135M 252M 16.78B 258M 1.73B 669M 8.29B 668M 653M 28.76B
Net Debt -1.78B -1.56B -1.44B -1.35B -2.53B -168B -2.58B -17.33B -6.7B -83.16B -6.7B -6.55B -288B -1.84B -1.61B -1.49B -1.39B -2.61B -174B -2.67B -17.88B -6.92B -85.8B -6.91B -6.76B -298B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26/06/26 $84.43 -0.09% 3,903,105
25/06/26 $84.51 +0.12% 1,986,569
24/06/26 $84.41 +2.78% 3,320,510
23/06/26 $82.13 +1.45% 2,307,236
22/06/26 $80.96 +2.51% 2,414,051
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
84.43USD
Average target price
93.93USD
Spread / Average Target
+11.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock